Acurx Pharmaceuticals Stock (ACXP) Explodes 218% as New Trial Moves Forward on 96% Cure Rate

Acurx Pharmaceuticals (ACXP) is having a record-breaking week after the company announced a major update for its lead drug, ibezapolstat. The stock has exploded by over 218% in just the last five days, with most of that jump happening after a massive Monday announcement. Investors are piling in because the company’s new clinical trial could completely change how doctors treat and prevent dangerous gut infections.

Claim 70% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions

• Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential

Acurx Moves Toward a One-Drug Solution

The main driver behind this rally is a new pilot study for patients with a recurring infection called C. difficile (CDI). This is a serious gut problem that often comes back even after treatment. Acurx says its drug, ibezapolstat, has already shown a 96% cure rate in earlier tests. Even more impressive, zero patients who were cured saw the infection return during the follow-up period. The company believes this drug could be a one-stop shop that both treats the infection and stops it from ever coming back.

Acurx Prepares for Phase 3 Trials

While the new pilot study is exciting, the real prize is the upcoming Phase 3 trials. This is the final step before a drug can be sold to the public. Management confirmed that they have received a clear roadmap from both U.S. and European regulators to start these international studies. This news has removed a lot of the mystery around the company’s future, giving investors more confidence that the drug is actually going to make it to market.

Investors Watch the Friday Morning Update

The timing of this rally is also tied to a big meeting. Acurx is set to report its full-year financial results on Friday morning, March 13. While the money numbers are important, most investors are waiting to hear more details about the Nexus of their research, the new clinical trials. With the stock already seeing massive after-hours moves, all eyes are on the opening bell to see if this record-breaking run can continue through the weekend.

Is ACXP a Good Stock to Buy?

According to data from two Wall Street analysts over the past three months, ACXP stock carries a Moderate Buy consensus rating based on two Buys.

The average 12-month ACXP price target stands at $17.50, implying a potential upside of 249.3% from the current price.

See more ACXP analyst ratings

Disclaimer & DisclosureReport an Issue